

1                   **Stabilization of  $\beta$ -catenin promotes melanocyte specification at the**  
2                   **expense of the Schwann cell lineage**

3  
4  
5                   **Sophie COLOMBO<sup>1-3#</sup>, Valérie PETIT<sup>1-3</sup>, Roselyne Y WAGNER<sup>1-3</sup>,**  
6                   **Delphine CHAMPEVAL<sup>1-3</sup>, Ichiro YAJIMA<sup>1-3</sup>, Franck GESBERT<sup>1-3</sup>,**  
7                   **Irwin DAVIDSON<sup>3,4</sup>, Véronique DELMAS<sup>1-3</sup>, and Lionel LARUE<sup>1-3\*</sup>**

8  
9  
10  
11                   (1) Institut Curie, PSL Research University, INSERM U1021, Normal and Pathological  
12                   Development of Melanocytes, Orsay, France,

13                   (2) Univ Paris-Sud, Univ Paris-Saclay, CNRS UMR 3347, Orsay, France,

14                   (3) Equipes Labellisées Ligue Contre le Cancer

15                   (4) Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/UNISTRA,  
16                   1 Rue Laurent Fries, 67404 Illkirch Cedex, France. Department of Functional Genomics and  
17                   Cancer.

18  
19                   # Current address: Columbia University Irving Medical Center, Institute for Genomic  
20                   Medicine, New York, NY, USA

21  
22                   \* Corresponding author:

23                   E-MAIL: [lionel.larue@curie.fr](mailto:lionel.larue@curie.fr)

24  
25                   Key words: pigmentation, cell fate, determination, proliferation, Mitf, FoxD3

26                   Running title :  $\beta$ -catenin, SCP and specification

29

30

31 **Summary statement**

32

33 Activation of  $\beta$ -catenin in bipotent Schwann-cell precursors during a specific developmental  
34 window, induces MITF and represses FoxD3 to promote melanoblast cell fate at the expense  
35 of Schwann cells in limbs.

36

37

38 **Abstract**

39 The canonical Wnt/ $\beta$ -catenin pathway governs a multitude of developmental processes in  
40 various cell lineages, including the melanocyte lineage. Indeed,  $\beta$ -catenin regulates *Mitf-M*  
41 transcription, the master regulator of this lineage. The first wave of melanocytes to colonize  
42 the skin is directly derived from neural crest cells, while a small number of second wave  
43 melanocytes is derived from Schwann-cell precursors (SCPs). We investigated the influence  
44 of  $\beta$ -catenin in the development of melanocytes of the first and second waves by generating  
45 mice expressing a constitutively active form of  $\beta$ -catenin in cells expressing tyrosinase.  
46 Constitutive activation of  $\beta$ -catenin did not affect the development of truncal melanoblasts,  
47 but led to a marked hyperpigmentation of the paws. By activating  $\beta$ -catenin at various stages  
48 of development (E8.5-E11.5), we showed that the activation of  $\beta$ -catenin in bipotent SCs  
49 favored melanoblast specification at the expense of Schwann cells in the limbs within a  
50 specific temporal window. In addition, hyperactivation of the Wnt/ $\beta$ -catenin pathway  
51 repressed *FoxD3* expression, which is necessary for Schwann cell development, through  
52 *Mitf-M* activation. In conclusion,  $\beta$ -catenin overexpression promotes SCP cell-fate decisions  
53 towards the melanocyte lineage.

54

## 55 INTRODUCTION

56 Multipotent neural-crest cells (NCC) in vertebrates constitute a transient population of cells  
57 arising from the dorsal part of the neural tube (Le Douarin and Kalcheim, 1999) that gives  
58 rise to numerous derivatives, such as neuronal and glial cells of the peripheral nervous  
59 system (PNS), smooth muscle cells, and melanocytes. Melanocytes produce melanin, a  
60 tyrosine-based polymer, in specialized organelles, the melanosomes. Classical melanocytes  
61 are pigmented cells, which (i) are found in the skin (dermis or epidermis), (ii) are involved in  
62 skin pigmentation, and (iii) are differentiated from melanoblasts derived from late-migrating  
63 NCC that have followed the dorso-lateral migratory pathway between the dermamyotome  
64 and the overlying ectoderm. These melanoblasts, referred to as first-wave melanoblasts, are  
65 specified as early as E8.5, before they start migrating along the dorso-lateral pathway from  
66 E10.5 (Petit and Larue, 2016). Between E11.5 and E13.5, most melanoblasts enter the  
67 epidermis, where they actively proliferate (Luciani et al., 2011). Between E15.5 and E17.5,  
68 epidermal melanoblasts migrate towards the forming hair follicles. In the furry parts of adult  
69 mice, most melanocytes are found in the hair matrix, whereas only few interfollicular  
70 melanocytes remain in the epidermis after birth (Hirobe, 1984). Epidermal melanocytes are  
71 abundant in the hairless parts of the body, such as the tail and paws (Silvers, 1979), except  
72 in the palms and soles, which have very few (Kunisada et al., 1998) and (Fig. S1).  
73 Melanocytes are considered to be non-classical if they are found in organs other than skin,  
74 not involved in skin pigmentation, and/or have not followed the dorso-lateral migratory  
75 pathway during development (Colombo et al., 2011). However, two types of non-classical  
76 melanocytes involved in skin pigmentation have been found, although they did not follow the  
77 dorso-lateral migratory route. One corresponds to a population of cells originating around the  
78 time of gastrulation, most likely within the mesoderm, and ultimately residing within the  
79 dermis (Kinsler and Larue, 2018). These melanoblasts are referred to as “mesodermal-wave  
80 melanoblasts”. The other is derived from Schwann cell precursors (SCPs) and is referred to  
81 as second-wave melanoblasts. SCPs are multipotent embryonic progenitors covering all  
82 developing peripheral nerves and originate from early ventrally-migrating NCC (Furlan and  
83 Adameyko, 2018). Previous studies have shown that a significant number of melanocytes in  
84 the skin of the trunk and limbs are produced from SCPs adjacent to spinal nerves that  
85 innervate the skin during development. Additionally, it was shown that the glial *versus*  
86 melanocyte fate is highly dependent on nerve contact (Adameyko et al., 2009). The authors  
87 showed that SCP-derived melanoblasts migrating ventrally from the DRG are specified  
88 around E11 in the mouse. While multiple elegant experiments had shown that the  
89 melanocytes and Schwann-cells share a common glial-melanogenic bipotent precursor and  
90 can be transdifferentiated into each other *in vitro* (Dupin et al., 2000; Dupin et al., 2003;  
91 Nitzan et al., 2013b; Real et al., 2006), the factors controlling the cell fate decisions between

92 these two lineages remained unclear. More recent experiments started elucidating the  
93 molecular pathways involved in the glial-melanocyte switch. Those bipotent progenitors  
94 express various proteins including Sox2, Sox9, Sox10, Fabp, Mitf, Pax3 and FoxD3  
95 (Adameyko and Lallemand, 2010). It has been shown that FoxD3 represses the expression  
96 of *Mitf* in zebrafish (Curran et al., 2009), in melanoma cell lines and cultured quail neural  
97 crest (Abel et al., 2013; Thomas and Erickson, 2009). Moreover, the downregulation of  
98 *FoxD3* is necessary for SCPs to follow a melanocyte fate (Adameyko et al., 2012; Jacob,  
99 2015; Nitzan et al., 2013b).

100  $\beta$ -catenin plays critical roles in multiple developmental processes, such as  
101 proliferation and cell fate decisions, owing to its dual function in cadherin-dependent cell-cell  
102 interactions and as a central component of the canonical Wnt signaling pathway (Aktary et  
103 al., 2016; Steinhart and Angers, 2018). Gain-of-function studies have shown induction of  
104 cellular proliferation of a number of cell types in transgenic mice expressing stabilized  $\beta$ -  
105 catenin (Gat et al., 1998; Imbert et al., 2001; Romagnolo et al., 1999). This pathway  
106 influences early melanoblast development, mainly through various common  $\beta$ -catenin/LEF  
107 targets, including Myc and *Ccdn1*, and a major downstream target of  $\beta$ -catenin in the  
108 melanocyte lineage, the *Mitf-M* transcription factor (Luciani et al., 2011). *Mitf-M* exerts  
109 survival and proliferation functions during the expansion of melanoblasts from the neural  
110 crest (Carreira et al., 2006; Hornyak et al., 2001) and regulates melanocyte differentiation by  
111 inducing the key enzymes of melanogenesis Tyr, *Tyrp1*, and *Dct* (Steingrimsson et al.,  
112 2004). The deletion of  $\beta$ -catenin specifically in migrating melanoblasts leads to  
113 hypoproliferation due to reduced *Mitf-M* expression (Luciani et al., 2011). Both the temporal  
114 and spatial fine-tuning of  $\beta$ -catenin and *Mitf-M* levels is required to regulate their various  
115 downstream targets and generate the required number of melanoblasts at the correct  
116 location during development. Apart from its role in neural crest induction and expansion, the  
117 Wnt/ $\beta$ -catenin signaling pathway has been implicated in neural-crest cell fate decisions. Mice  
118 deficient for both *Wnt1* and *Wnt3a* exhibit a marked deficiency of *Dct*-positive neural-crest-  
119 derived melanoblasts (Ikeya et al., 1997).  $\beta$ -catenin has also been directly associated with  
120 melanoblast cell-fate specification in various species using  $\beta$ -catenin gain- and loss-of-  
121 function approaches. In zebrafish, injection of  *$\beta$ -catenin* mRNA into a subpopulation of  
122 migrating NCCs induces the formation of pigmented cells (Dorsky et al., 1998). In mice, the  
123 conditional ablation of  *$\beta$ -catenin* in premigratory NCCs leads to a loss of melanocytes and  
124 sensory neurons (Hari et al., 2002), whereas its activation promotes the formation of the  
125 sensory neuronal lineage at the expense of other neural-crest derivatives (Lee et al., 2004).  
126 A change in cell-fate specification, rather than a proliferation defect, underlies the loss of  
127 melanocytes. Moreover, the expression of a constitutive activated form of  $\beta$ -catenin in

128 bipotent cardiac neural-crest cells, known to produce mainly smooth muscle cells and few  
129 melanocytes, promotes the melanocyte fate at the expense of the smooth-muscle fate in the  
130 *ductus arteriosus* of embryonic hearts, leading to patent ductus arteriosus, a congenital  
131 disease (Yajima et al., 2013). Overall, these results demonstrate the essential role of the  
132 Wnt/ $\beta$ -catenin pathway in NCC and melanocyte fate determination.

133 We investigated the influence of  $\beta$ -catenin on the first- and second-wave of  
134 melanocyte development. A mouse genetic approach was used to express a conditional  
135 mutant of  $\beta$ -catenin ( $\beta$ cat $\Delta$ ex3), known to be hyperactive (Harada et al., 1999), at specific  
136 times and in specific neural-crest-cell derivatives using either constitutive or inducible Cre  
137 lines under the control of the Tyrosinase promoter (Delmas et al., 2003; Yajima et al., 2006).  
138 We observed that constitutive activation of  $\beta$ -catenin led to hyperpigmentation of the paws  
139 due to promotion of the melanocyte fate at the expense of the glial fate at the time of SCP  
140 specification. At the molecular level, we show that  $\beta$ -catenin overexpression represses  
141 *FoxD3* expression through *Mitf*, thereby allowing SCPs to follow a melanocyte fate.

142

## 143 RESULTS

144

### 145 **Constitutively active $\beta$ -catenin ( $\beta$ cat $\Delta$ ex3) induces hyperpigmentation of the paws**

146 On a C57BL/6 background, we generated mice producing a constitutively active form of  $\beta$ -  
147 catenin (Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>flox/+</sup> =  $\beta$ cat $\Delta$ ex3) in cells of the Tyr::Cre lineage by crossing  
148 Tyr::CreA mice (Delmas et al., 2003) with mice harboring a floxed exon 3 of  $\beta$ -catenin  
149 (Harada et al., 1999; Yajima et al., 2013).  $\beta$ cat $\Delta$ ex3 mutant mice displayed strong  
150 hyperpigmentation of the palms and soles with full penetrance (Figs. 1A, S2A). However, we  
151 did not observe strong hyperpigmentation on the back of the paws (Fig. S2A). Palmoplantar  
152 hyperpigmentation was already present at birth and was particularly striking at P5 (Fig. 1A).  
153 Transversal sections at the metatarsal level of paws from post-natal day 1 (P1) and P5  
154 newborn mice revealed high levels of pigmentation on the ventral side of the  $\beta$ cat $\Delta$ ex3  
155 mutant paws, whereas it was absent from the wild-type (WT) paws (Figs. 1B, S2B).  
156 Moreover, this pigmentation was localized in the dermis, directly under the epidermis, as well  
157 as more deeply in the palmoplantar mesenchyme.

158

### 159 **$\beta$ -catenin is properly defloxed and activated in $\beta$ cat $\Delta$ ex3 melanoblasts and 160 melanocytes**

161 The transcriptional activity of  $\beta$ cat $\Delta$ ex3 was previously assessed with the “TOP and FOP”  
162 flash luciferase reporter assay and was shown to be five times higher than that of WT  $\beta$ -  
163 catenin (Yajima et al., 2013). Deletion of exon3 in  $\beta$ cat $\Delta$ ex3 mice was verified by PCR on  
164 genomic DNA extracted from mouse tails containing melanocytes (Fig. S3A,B). We verified  
165 the presence of  $\beta$ -catenin in the nucleus, a marker of its stabilization/activation, by  
166 immunofluorescence of skin sections during development and after the birth of Tyr::Cre<sup>o</sup>;  
167 Dct::LacZ (WT-LacZ) and Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>flox/+</sup>; Dct::LacZ ( $\beta$ cat $\Delta$ ex3-LacZ) mice using  $\beta$ -  
168 galactosidase expression as a melanoblast/melanocyte marker (MacKenzie et al., 1997;  
169 Yajima et al., 2013).  $\beta$ -catenin was present in the nucleus of  $\beta$ cat $\Delta$ ex3 melanoblasts in the  
170 epidermis of E14.5 embryos whereas it was localized at the membrane in WT mice (Fig.  
171 S3C). These results show that  $\beta$ -catenin was properly defloxed and activated in  $\beta$ cat $\Delta$ ex3  
172 melanoblasts and melanocytes.

173

### 174 **The $\beta$ cat $\Delta$ ex3 mutation does not affect coat color nor truncal melanoblast proliferation**

175  $\beta$ cat $\Delta$ ex3 mutant mice have no distinctive coat color, ear, or tail phenotype (Fig. S4A). The  
176 mutation of  $\beta$ -catenin is induced around E9.0, as the Tyr::Cre transgene begins to be  
177 expressed, after dorso-laterally-migrating melanoblasts have been determined. We  
178 evaluated the number of WT-LacZ and  $\beta$ cat $\Delta$ ex3-LacZ melanoblasts in the truncal region of

179 E13.5 to E18.5 embryos. From E13.5 to E15.5, the number of melanoblasts was determined  
180 on whole mount embryos stained with X-gal in a region localized between the fore- and hind-  
181 limbs (ranging from approximately somite 13 to somite 25). There was no significant  
182 difference in melanoblast numbers at these stages between WT and mutant embryos (Fig.  
183 S4B). At E16.5 and E18.5, truncal melanoblasts were counted on embryo sections  
184 immunostained for  $\beta$ -galactosidase (Fig. S4C). Few or no melanoblasts were present in the  
185 dermis at these stages, as previously described for WT embryos (Luciani et al., 2011). The  
186 presented figures correspond to epidermal and hair-follicle melanoblasts. At E16.5, hair  
187 follicles have just initiated invagination from the epidermis while at E18.5, they extend into  
188 the dermis and numerous melanoblasts can be found entering and within the hair follicles.  
189 There was no difference in melanoblast numbers between WT and mutant mice at these two  
190 stages (Fig. S4C). We also investigated melanoblast proliferation in the skin of the trunk  
191 using bromodeoxyuridine (BrdU) incorporation assays on embryos collected at E16.5 and  
192 E18.5. There was no significant difference in the percentage of BrdU-positive melanoblasts  
193 at these stages (Fig. S4D). Overall, these results show that hyperactivation of  $\beta$ -catenin does  
194 not influence the development of already determined dorso-laterally-migrating melanoblasts.

195

### 196 **Hyperpigmentation of $\beta$ cat $\Delta$ ex3 ventral paws is due to an elevated number of** 197 **melanocytes**

198 X-gal staining of transversal sections of P1 WT-LacZ and  $\beta$ cat $\Delta$ ex3-LacZ paws revealed  
199 numerous Dct-positive cells colocalized with strong pigmentation in the mutant palms and  
200 soles, whereas they were absent in WT littermates (Fig. 2A,B). X-gal staining also labeled  
201 the nerves in the posterior paws (Fig. 2B), but not in the anterior paws (Fig. 2A) (MacKenzie  
202 et al., 1997). These nerve-associated Dct::LacZ positive-cells were most likely melanoblasts  
203 and/or bipotent SCP and not nerve projections, as we observed a similar pattern of Dct-  
204 positive cells colocalized with pigment in both the anterior and posterior paws. The  
205 pigmentation pattern in mutant paws was located around the nerves, most likely following  
206 nerve projections (Fig. 2B). In the phalanges, pigmentation was strikingly localized around  
207 the bones of the digits (Fig. 2B), whereas at the metacarpal/metatarsal level, it was mostly  
208 localized under the epidermis (Fig. 2A). These results suggest that ectopic melanocytes are  
209 present in the mutant paws.

210

### 211 **Hyperpigmentation of $\beta$ cat $\Delta$ ex3 ventral paws is due to abnormal invasion of** 212 **melanoblasts during development**

213 The  $\beta$ cat $\Delta$ ex3 paw phenotype was already visible at birth, when the mice are normally  
214 unpigmented. It is thus likely the consequence of altered developmental processes. We



215 analyzed the location and number of melanoblasts in E13.5 limbs and paws, when  
216 melanoblasts have started their migration to the limbs but have not yet reached the paws.  
217 There was no difference in melanoblast distribution between WT and mutant embryos at this  
218 stage (Fig. S5A). A difference started to appear at E14.5. Anterior mutant paws displayed  
219 melanoblasts ventrally in the palms, as well as few melanoblasts dorsally, whereas they were  
220 not present or in very low numbers in WT embryos (Figs. 3A, S5B). There was a statistically  
221 significant increase in the number of Dct-positive melanoblasts in the distal region of the  
222 ventral limbs, but not in the proximal region of the limb (Fig. 3C). While there was a tendency  
223 to increased numbers also on the dorsal side of mutant paws, the difference was not  
224 statistically significant (Fig. 3C). No phenotype was yet visible in the posterior paws at this  
225 stage (not shown). At E15.5, the phenotype was clearly visible ventrally in mutant paws.  
226 Large numbers of melanoblasts were found in the palms and soles and proximal part of the  
227 digits, whereas they were mostly absent from the WT paws. Melanoblasts could also be seen  
228 in the digits on the dorsal side of the paws (Figs. 3B, S5C). In WT mice, a clear front of  
229 migration of melanoblasts was apparent at the junction between the limb and paw (Figs. 3A,  
230 S5, black dotted lines). In mutant mice, however, melanoblasts appeared to cross this  
231 junction and continue their migration into the palms, soles, and digits. Altogether, these  
232 results suggest that constitutively active  $\beta$ -catenin during the establishment of the  
233 melanocyte lineage induces melanoblast colonization into the palms and soles.

234  
235 **Melanocytes from the palms and soles originate from the second wave of**  
236 **melanoblasts.**

237 Melanocytes are specified from the neural crest around E8.5-E9.0 (Le Douarin and  
238 Kalcheim, 1999), while they seem to specify from SCPs around E10.5-E11.5 (Fig. S6)  
239 (Adameyko et al., 2009; Van Raamsdonk and Deo, 2013). We used temporal induction of  
240  $\beta$ cat $\Delta$ ex3 to reveal the origin of the melanoblasts invading the soles and palms and leading  
241 to the hyperpigmentation phenotype. We generated Tyr::CreER<sup>T2/0</sup>;  $\beta$ catex3<sup>fllox/+</sup> mice  
242 ( $\beta$ cat $\Delta$ ex3-Tam), induced activated  $\beta$ -catenin at either E8.5, E10.5 or E11.5 with 4OH-  
243 tamoxifen, and evaluated the location and number of melanoblasts in the distal part of the  
244 limbs at E15.5. The tamoxifen induction at E8.5 and E11.5 appeared to affect neither the  
245 number nor localization of melanoblasts at E15.5 in the distal region of the ventral paws (Fig.  
246 3D,F,G,I). However, tamoxifen induction at E10.5 resulted in a clear increase in the number  
247 of melanoblasts in the distal region of the ventral paws (Fig. 3E,H). These results suggested  
248 that SCPs actually specify into melanocytes as early as E10.5 and that hyperactivation of  $\beta$ -  
249 catenin in those bipotent progenitors at that specific time promotes the melanoblast fate. We  
250 thus estimated the number of Schwann cells (Gfap-positive cells) and melanoblasts (Mitf-

251 positive cells) in  $\beta\text{cat}\Delta\text{ex3}$  limbs. Expression of  $\beta\text{cat}\Delta\text{ex3}$  led to an increased number of  
252 melanoblasts and a decreased number of Schwann cells in the palms (Fig. 4). These results  
253 suggested that the expression of a constitutively active form of  $\beta$ -catenin in glial-melanogenic  
254 bipotent progenitors at the time of their fate determination promoted their differentiation into  
255 melanoblasts of the second wave at the expense of glial cells. Because SCPs are located  
256 along and migrate with axons of peripheral nerves, the ectopic melanocytes observed in the  
257 paws of  $\beta\text{cat}\Delta\text{ex3}$  mice would likely have migrated away from these nerves.

258

### 259 **$\beta$ -catenin promotes the SCP-derived melanocyte fate through *Mitf* repression of *FoxD3***

260 The downregulation of *FoxD3* in SCPs is necessary to allow emergence of melanocyte cells  
261 (Adameyko et al., 2012; Jacob, 2015; Nitzan et al., 2013a) prompting us to ask whether  
262 activation of  $\beta$ -catenin signaling affected *FoxD3* expression. Constitutive activation of  $\beta$ -  
263 catenin signaling by knocking down *APC* using an siRNA in HEI-193 human schwannoma  
264 cells resulted in a significant decrease of *FOXD3* mRNA level compared to control scrambled  
265 siRNA (siScr) transfected cells (Fig. 5A). As a control, we showed that under the same  
266 conditions the levels of *AXIN2* mRNA, a well-known downstream target of  $\beta$ -catenin, was  
267 induced (Fig. 5B). It has previously been shown that *FOXD3* overexpression in melanoma  
268 cell lines or cultured quail neural crest cells resulted in repression of *MITF* expression (Abel  
269 et al., 2013; Thomas and Erickson, 2009). In a converse experiment, we show here that  
270 siRNA-mediated *MITF* silencing in 501mel and SK28 human melanoma cells led to  
271 upregulation of *FOXD3* (Fig. 5C-F). ChIP-seq in 501mel cells revealed that MITF occupied  
272 several sites at the *FOXD3* locus in a putative distal enhancer. One of these sites was co-  
273 occupied by SOX10 and marked by H3K27ac, BRG1 and H2AZ (Fig. 5G). MITF ChIP-seq in  
274 primary human melanocytes also showed MITF binding to the distal enhancer in particular at  
275 the site co-occupied by SOX10, but in addition, binding to a site in the proximal *FOXD3*  
276 promoter (Webster et al., 2014). At each site, a consensus E-box sequence was present  
277 along with a SOX10-binding motif at the distal enhancer. Moreover, these binding sequences  
278 were present at the otherwise well-conserved syntenic regions at the mouse *Foxd3* locus  
279 (Fig. 5G). Taken together, these observations strongly suggested the presence of a  
280 reciprocal regulatory feedback loop in the melanocytic lineage where *FOXD3* repress *MITF*  
281 and *MITF* repress *FOXD3*. Since the level of *MITF* expression and activity depends on  
282 numerous factors in the melanocytic lineage, this equilibrium may be rapidly shifted in favor  
283 of *MITF* when one of these molecular pathways, such as Wnt/ $\beta$ -catenin, is induced leading to  
284 decreased *FOXD3* levels and altered cell fate (see schematic on Fig. 6).

285

## 286 **DISCUSSION**

287 Here, we show that a constitutively active form of  $\beta$ -catenin ( $\beta$ cat $\Delta$ ex3) differentially affects  
288 melanoblast development in the trunk and paws. In the trunk region, expression of  $\beta$ cat $\Delta$ ex3  
289 did not induce any major defects in developing melanoblasts, whereas it induced strong  
290 palmo-plantar hyperpigmentation of the paws. This hyperpigmentation was due to the  
291 abnormal presence of melanocytes derived from the second wave of melanoblasts.  
292 Melanoblasts migrating in the palms and soles of the mutant mice were seen as early as  
293 E14.5, whereas they were mostly absent in WT mice. These results show that once  
294 specified,  $\beta$ cat $\Delta$ ex3 does not influence the development of melanoblast of the first wave, but  
295 instead controls SCP cell-fate decisions between glial and melanocyte lineages in the ventral  
296 migratory pathway. According to these results, the contribution of SCPs to melanocytes in  
297 the adult appeared to be restricted to the limbs.

298

### 299 **Hyperpigmentation of the paws**

300 Hyperpigmentation of the palms and soles was already described in humans and mice after  
301 cell non-autonomous induction. Human palmoplantar fibroblasts express the Wnt/ $\beta$ -catenin  
302 signaling inhibitor DKK1, which inhibits melanocyte function and growth by regulating  $\beta$ -  
303 catenin (Yamaguchi et al., 2004; Yamaguchi et al., 2008). Downregulation of  $\beta$ -catenin leads  
304 to the inhibition of Mitf-M expression, and of its downstream target Tyrosinase, the key  
305 enzyme of melanogenesis. Increasing  $\beta$ -catenin levels in SCP-derived melanocytes may  
306 counteract the effects of Dkk1 in palmoplantar skin, promoting melanocyte differentiation  
307 after inducing Mitf and Tyrosinase. Overexpression of Kitl (Steel factor) in the basal layer of  
308 the epidermis in mice induces palmoplantar hyperpigmentation (Kunisada et al., 1998). The  
309 authors found melanoblasts in the footpads of E16.5 mutant embryos, whereas they were not  
310 present in WT littermates. As Kit signaling is involved in melanoblast migration, they  
311 proposed that increased Kit signals promote migration of melanoblasts throughout the entire  
312 paw epithelium. This explanation is certainly valid. However, Kit signaling in melanocytes  
313 indirectly regulates  $\beta$ -catenin, through the PI3K pathway, and Mitf-M, through the MAPK  
314 pathway. Thus, in keeping with the results obtained here, an alternative and/or  
315 complementary explanation for the palmoplantar hyperpigmentation is enhanced  
316 melanoblast specification from SCPs.

317

### 318 **Specification**

319 As previously mentioned,  $\beta$ -catenin is involved in cell-fate specification, a process involving  
320 complex combinations of cell intrinsic and extracellular signals that need to be correctly  
321 delivered in time and space. The role of  $\beta$ -catenin in the specification of first wave

322 melanocytes has been clearly demonstrated. The inactivation of  $\beta$ -catenin in NCC prior to  
323 melanoblast specification using *Wnt1::Cre* shows that  $\beta$ -catenin is essential for the  
324 generation of melanoblasts. The absence of  $\beta$ -catenin apparently does not impair early SCP  
325 specification, as specific markers are produced (Hari et al., 2002). Thus, SCPs and second  
326 wave melanocytes still form in these animals. This series of experiments showed the critical  
327 function of Wnt signaling in driving early melanoblast specification and could explain the  
328 absence of first-wave melanocytes (*i.e.* migrating dorso-laterally), but the importance of  $\beta$ -  
329 catenin in the generation of second wave melanocytes was still unknown. As Schwann cells  
330 and second wave melanocytes share a common SCP precursor, we hypothesized that  $\beta$ -  
331 catenin in the  $\beta$ cat $\Delta$ ex3 mutant mice is activated in SCPs that migrate via the ventral  
332 pathway, altering their fate and promoting their differentiation into melanocytes. Whereas  
333 neural progenitors and glial cells express the *Foxd3* transcription factor, it is not expressed in  
334 melanoblasts (Kos et al., 2001). As *Mitf* is the key transcription factor specifying the  
335 melanocyte lineage and knowing that SCPs express *Foxd3*, *Mitf* and *Sox10*, it is likely that  
336 SCP fate is governed by the relative amounts/activities of *Foxd3* and *Mitf*. In agreement with  
337 this hypothesis, constitutive activation of  $\beta$ -catenin in Schwannoma cells led to *FOXD3*  
338 repression, whereas *MITF* silencing up-regulated *FOXD3* expression in melanoma cell lines.  
339 Moreover, *MITF* binds to regulatory elements at the *FOXD3* locus in human melanoma cells  
340 and primary melanocytes and may therefore directly inhibit its expression. In contrast,  
341 overexpression of *FOXD3* in melanoma cell lines represses *MITF* expression (Abel et al.,  
342 2013; Thomas and Erickson, 2009). Together these observations support the idea that a  
343 direct and reciprocal negative regulation of *FOXD3* and *MITF* expression can affect SCP  
344 fate. This model is reminiscent of the reciprocal negative regulation seen with *MITF* and *JUN*  
345 that affects the phenotype switch between melanocytic and undifferentiated melanoma cell  
346 states (Riesenberg et al., 2015). Based on these observations, we propose that high  $\beta$ -  
347 catenin levels in SCP at the time of their specification increases *Mitf* expression, hence  
348 repressing *FoxD3* expression and enhancing melanocyte specification at the expense of glia.  
349 Such a model is supported by the reduced numbers of *Gfap*-positive cells and increased  
350 numbers of *Mitf*-positive or *Dct*-positive cells observed in the paws of  $\beta$ cat $\Delta$ ex3 mice,  
351 suggesting that a cell fate switch occurred.

352

### 353 **Acral melanoma**

354 Although the number of melanocytes in the soles of the feet and palms of the hands are very  
355 limited, these cells may transform in acral melanoma (ALM). ALM and nodular melanoma  
356 (NM) are more aggressive than superficial spreading melanoma (SSM). The percentage of  
357 ALM is higher in Asians (50%) than in Caucasians (10%). This is because NM and SSM are

358 very rare in Asians, but the risk to develop an ALM appears to be similar between Asians and  
359 Caucasians. At the molecular level, the main mutations in ALM and non-ALM are similar;  
360 they include mutations in the *BRAF*, *NRAS*, *NF1*, and *KIT* genes, but the proportions are  
361 different (Moon et al., 2018; Zebary et al., 2013). NM and SSM arise from melanocytes  
362 determined from the first wave of melanoblasts, while ALM arises from melanocytes derived  
363 from the second wave of melanoblasts. While sun exposure is a well-established cause for  
364 melanoma development, the soles and palms are non-sun-exposed regions, raising the issue  
365 of the importance of the embryonic origin of melanocytes in melanomagenesis and how this  
366 may influence their aggressivity when transformed.

367

### 368 **Conclusion**

369  $\beta$ -catenin appears to play a complex role in the melanocyte lineage, depending on tight  
370 regulation of its levels and time and place of induction. We show here that expression of  
371  $\beta$ cat $\Delta$ ex3 after specification of the melanoblasts of the first wave in Tyr::Cre- and  
372 Tyr::CreER<sup>T2</sup>-expressing cells does not appear to affect melanoblast development in the  
373 dorso-lateral pathway, but favors melanoblast specification in the ventral pathway.

374

375

## 376 **MATERIALS AND METHODS**

### 377 **Transgenic mouse generation and genotyping**

378 Animal care, use, and experimental procedures were conducted in accordance with  
379 recommendations of the European Community (86/609/EEC) and Union (2010/63/UE) and  
380 the French National Committee (87/848). Animal care and use were approved by the ethics  
381 committee of the Curie Institute in compliance with the institutional guidelines.

382  
383 Mice with conditional constitutive stabilization of  $\beta$ -catenin were generated by mating  
384 Tyr::CreA and Tyr::Cre-ER<sup>T2-Lar</sup> (designated in the text as Tyr::Cre-ER<sup>T2</sup>) transgenic mice  
385 (Delmas et al., 2003; Yajima et al., 2006) with animals homozygous for a floxed allele of  $\beta$ -  
386 catenin, with LoxP sites flanking exon 3 ( $\Delta$ ex3) (Harada et al., 1999). Transgenic mice were  
387 maintained on a pure C57BL/6J background (backcrossed at least 10 times). All animals  
388 were housed in specific pathogen-free conditions in the animal facility. Mice were genotyped  
389 using DNA isolated from tail biopsies using standard PCR conditions. The Tyr::Cre transgene  
390 (0.4 kb fragment) was detected by PCR, as previously described (Delmas et al., 2003). For  
391 detection of the floxed (570bp) and WT (376bp) alleles of the  $\beta$ -catenin gene, PCR  
392 amplification was carried out with the forward primer (LL523) 5'-GAC ACC GCT GCG TGG  
393 ACA ATG-3' and the reverse primer (LL524) 5'-GTG GCT GAC AGC AGC TTT TCT G-3'.  
394 The forward primer (LL667) 5'-CGT GGA CAA TGG CTA CTC A-3' and the reverse primer  
395 (LL668) 5'-CTG AGC CCT AGT CAT TGC AT-3' were used for detection of the WT (715bp)  
396 and deleted (450bp) alleles of the  $\beta$ -catenin gene. The PCR conditions were as follows: 5  
397 min at 94°C followed by 35 cycles of 20 s at 94°C, 30 s at 56.5°C, 45 s at 72°C, and a final  
398 extension of 10 min at 72°C.

399

### 400 **Tamoxifen injection**

401 Pregnant C57BL/6J mice were injected intraperitoneally at E8.5, E10.5 or E11.5 with  
402 tamoxifen (Sigma) diluted in corn oil. An amount of 0.5mg of tamoxifen was injected for 20g  
403 of body weight. This dose of Tamoxifen was not optimal but higher doses induced embryonic  
404 death and resorption of the embryos.

405

### 406 **Histology**

407 Mice were crossed with Dct::LacZ (MacKenzie et al., 1997) and the resulting embryos  
408 collected at various times during pregnancy. Embryos were stained with X-gal, as previously  
409 described (Delmas et al., 2003). Paws of new-born mice at P1 were dissected, washed in  
410 PBS, and fixed by incubation in 0.25% glutaraldehyde in PBS for 50 min at 4°C. They were  
411 then incubated in 30% sucrose/PBS overnight, followed by 30% sucrose/50% OCT/PBS for

412 5h and embedded in Optimal Cacodylate Compound (OCT). Cryosections (8 $\mu$ m thick) were  
413 stained either with heamatoxylin and eosin or X-gal as follows: they were washed twice in  
414 PBS at 4°C, and incubated twice, for 10 min, in permeabilization solution (0.1M phosphate  
415 buffer pH7.3, 2mM MgCl<sub>2</sub>, 0.01% sodium deoxycholate, 0.02% NP-40) at room temperature.  
416 They were then incubated in staining solution (0.4mg/mL 5-bromo-4-chloro-3-indolyl-D-  
417 galactosidase, 2 mM potassium ferricyanide, 2 mM potassium ferrocyanide, 4 mM MgCl<sub>2</sub>,  
418 0.01% sodium deoxycholate, and 0.02% NP-40 in PBS) overnight at 30°C. Sections were  
419 post-fixed in 4% PFA overnight at 4°C, washed in PBS, and stained with eosin. Paws of  
420 newborn mice at P5 were fixed in 4% PFA, dehydrated, and embedded in paraffin by  
421 standard methods. Paraffin sections (7 $\mu$ m thick) were stained with eosin.

422

### 423 **Immunostaining**

424 Mice were crossed with Dct::LacZ and the embryos collected at various stages of  
425 development. Newborn skin was dissected from the back of the mice. Embryos and skins  
426 were washed in PBS and fixed by overnight incubation in 4% PFA. They were then incubated  
427 in 30% sucrose/PBS overnight, followed by 30% sucrose/50% OCT/PBS for 5 h and  
428 embedded in OCT. Cryosections (7  $\mu$ m thick) were washed with PBS-Tween 0.1% (PBT) for  
429 10 min. Antigens were then retrieved by incubation for 20 min in citric acid buffer (pH 7.4) at  
430 90°C. Non-specific binding was blocked by incubation with 2% skimmed milk powder in PBT.  
431 Sections were incubated overnight at 4°C with various primary antibodies. Rabbit polyclonal  
432 antibody against  $\beta$ -catenin (Abcam ab6302) and chicken polyclonal antibody against  $\beta$ -  
433 galactosidase (Abcam ab9361) were used. Sections were washed three times in PBST for 5  
434 min each and incubated with secondary antibodies for 1 h at 37°C. The secondary antibodies  
435 used were donkey Alexa 488-anti-rabbit and donkey Alexa 555-anti-chicken (Molecular  
436 Probes). Sections were incubated in DAPI for 10 min, washed three times in PBT, for 10 min  
437 each, and mounted in mounting media containing N-propylgalate. Conventional fluorescence  
438 photomicrographs were obtained with a Leica DM IRB inverted routine microscope.

439

### 440 **Whole mount immunostaining**

441 E13.5 and E15.5 embryos paws were collected and fixed in 4% PFA-PBS pH7.5  
442 (Euromedex) for 6 hours prior washing them three times in PBT. Paws were dehydrated in a  
443 series of PBS/methanol incubation (25%, 50%, 75% and 100%) for 10min each. Paws were  
444 incubated 24 hours in methanol at 4°C prior bleaching them for 24h in a mixture of 1/3 H<sub>2</sub>O<sub>2</sub>  
445 and 2/3 methanol 30%. Paws were washed three times in methanol prior post-fixed them  
446 overnight in 1/5 DMSO and 4/5 pure methanol. Paws were sequentially rehydrated in  
447 PBS/methanol (75%, 50%, 25% and 0%) for 10 min each prior washing them twice in PBT.

448 Paws were incubated overnight at room temperature in PBS containing 5% Donkey serum,  
449 1% BSA and 20% DMSO. After blocking, paws were incubated with primary antibody(ies) in  
450 the blocking solution at 1/1,000 for five days at RT. Primary antibodies were rabbit against  
451 neurofilament (Abcam ab9034), mouse against Gfap (Sigma C9205 & Cell Signalling  
452 Technology 3670) and goat against Mitf (R&D system AF5769). Secondary antibodies were  
453 diluted in the blocking solution: alexaFluor 555 (Invitrogen A-31572), alexaFluor488  
454 (Invitrogen A21202) and alexaFluor633 (Invitrogen A-21082) for overnight at RT. Staining  
455 was ended after incubation of the paws in Dapi for 4 hours at RT. Embryos were dehydrated  
456 in PBS/methanol (25%, 50%, 75% and 100%) for 10min each at RT. Chambers made by  
457 1mm thick Fastwell (Sigma) coated on a glass slide was used to incorporate the paws. Each  
458 paw was fixed on to the glass slide with 1% NuSieve Agarose (Sigma) and covered with  
459 methanol. After three washes with methanol, paws were incubated twice for 5min with  
460 methanol 50% BABB (1/3 benzylalcohol and 2/3 benzylbenzoate, from Sigma), and then  
461 three times in pure BABB for 5min each (or until the sample is cleared). The chamber was  
462 closed with coverslip and sealed with nail polish prior examination under the microscope.

463

#### 464 **Confocal imaging and ImageJ treatment for 3D reconstruction**

465 Z-sections were acquired every 5  $\mu\text{m}$  for the dorsal and ventral part of the limb with a  
466 Confocal Leica SP5 microscope. Then, the plugin PureDenoise was used on the stack to  
467 increase the signal, and finally the filter subtract background (20) was used to remove the  
468 remaining background. 3D reconstructions were performed from stacks containing the same  
469 number of sections and the same biological structures in WT and mutants, using 3D project  
470 in *ImageJ* without interpolation.

471

#### 472 **BrdU labelling**

473 Melanocyte proliferations were analyzed using BrdU labelling *in vivo* on embryos at various  
474 stages of development. BrdU (100  $\mu\text{g}/\text{mL}$ , BD Biosciences) was injected intra-peritoneally into  
475 the pregnant mother 2 h before sacrifice, in the form of two 50- $\mu\text{g}/\text{mL}$  injections administered  
476 at 20-min intervals. Embryos were collected for immunohistochemistry. They were fixed and  
477 stained, as described above, with mouse monoclonal anti-BrdU antibody (BD Biosciences)  
478 and chicken polyclonal anti- $\beta$ -galactosidase antibody (Abcam). Donkey Alexa 488-anti-  
479 mouse and donkey Alexa 555-anti-chicken (Molecular Probes) were used as secondary  
480 antibodies.

481

#### 482 **Melanoblast counts on the paws**



483 Pictures of Xgal stained paws were taken using a binocular magnifying glass with a 1x  
484 objective. Proximal area (from the body to the migrating front, between the dotted yellow and  
485 black lines) and distal area (after the black dotted line) were delimited on the picture. Blue  
486 dots (melanoblasts) were counted using *ImageJ* software. At least 5 embryos were counted  
487 for each genotype at each stage in both areas.

488

#### 489 **Cell culture and siRNA-mediated knockdown**

490 501mel and SK28 human melanoma cell lines were grown in RPMI 1640 media (GIBCO)  
491 supplemented with 10% FCS (GIBCO) and 1% Penicillin-Streptomycin (GIBCO). HEI-193  
492 Schwannoma cells were grown in DMEM media (GIBCO) supplemented with 10% FCS  
493 (GIBCO) and 1% Penicillin-Streptomycin (GIBCO). Cells were maintained at 37°C in a  
494 humidified atmosphere containing 5% CO<sub>2</sub>. siRNA targeting human MITF (M-008674) and  
495 APC (L-003869) were purchased from Dharmacon. Si Scramble (siSCR), with no known  
496 human targets, was purchased from Eurofins Genomics. Cells were transfected with 100  
497 pmol siRNA or siScr with Lipofectamine2000 (Invitrogen) and assayed for mRNA expression  
498 48h post-transfection.

499

#### 500 **RNA extraction and RT-qPCR**

501 Total RNA was extracted from cell lines using the miRNeasy kit (Qiagen). M-MLV reverse  
502 transcriptase (Invitrogen) was used according to the manufacturer's protocol to synthesize  
503 cDNA from 1 µg total RNA in combination with random hexamers. Quantitative RT-PCR was  
504 performed with the iTaq universal Sybrgreen Supermix (BIORAD) and primers listed below,  
505 using a QuantStudio 5 thermocycler (Applied Biosystem) in a final reaction volume of 25 µL  
506 under the following conditions: 95°C for 1.5min, 40 cycles of 95°C for 30s, 60°C for 60s, with  
507 a final melting curve analysis. Relative expression was determined by the comparative  $\Delta\Delta C_t$   
508 method. PCR primers: FOXD3 f: 5'-CAT CCG CCA CAA CCT CTC-3'; FOXD3 r: 5'-CAT  
509 ATG AGC GCC GTC TG-3'; MITF f: 5'-CTA TGC TTA CGC TTA ACT CCA-3'; MITF r: 5'-  
510 TAC ATC ATC CAT CTG CAT ACA G-3'; AXIN2 f: 5'-CCT AAA GGT CGT GTG TGG CT-3';  
511 AXIN2 r: 5'-GTG CAA AGA CAT AGC CAG AAC C-3'; TBP f: 5'-CAC GAA CCA CGG CAC  
512 TGA TT-3'; TBP r: 5'-TTT TCT TGC TGC CAG TCT GGA C-3'.

513

#### 514 **Statistical analysis**

515 Statistical tests are detailed in the figure legends. All data are presented as mean  $\pm$  SEM.  
516 Statistical analyses were performed with Prism 5 software (GraphPad).

517

518

519 **ACKNOWLEDGEMENTS**

520 We are grateful to Dominique Lallemand for providing HEI-193 human schwannoma cell line.  
521 We thank the teams caring for the imaging, histology and animal colony facilities of the  
522 Institut Curie, especially Pauline Dubreuil and Mirella Miranda.

523

524 **FUNDING**

525 This work was supported by the Ligue Contre le Cancer, Fondation ARC, INCa, ITMO  
526 Cancer, and is under the program «Investissements d’Avenir» launched by the French  
527 Government and implemented by ANR Labex CeTisPhyBio (ANR-11-LBX-0038 and ANR-  
528 10-IDEX-0001-02 PSL). S.C. was supported by fellowships from MENRT and FRM. R.Y.W.  
529 was supported by fellowships from MENRT and ARC.

530

531 **CONFLICT OF INTEREST**

532 S.C. serves a consultant for Q-State Biosciences, Inc. All other authors declare no conflict of  
533 interest.

534

535 **REFERENCES**

536

537

538 **Abel, E. V., Basile, K. J., Kugel, C. H., 3rd, Witkiewicz, A. K., Le, K., Amaravadi, R. K.,**  
539 **Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013).** Melanoma  
540 adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. *J*  
541 *Clin Invest* **123**, 2155-2168.

542 **Adameyko, I. and Lallemand, F. (2010).** Glial versus melanocyte cell fate choice: Schwann  
543 cell precursors as a cellular origin of melanocytes. *Cellular and molecular life*  
544 *sciences : CMLS* **67**, 3037-3055.

545 **Adameyko, I., Lallemand, F., Aquino, J. B., Pereira, J. A., Topilko, P., Muller, T., Fritz,**  
546 **N., Beljajeva, A., Mochii, M., Liste, I., et al. (2009).** Schwann cell precursors from  
547 nerve innervation are a cellular origin of melanocytes in skin. *Cell* **139**, 366-379.

548 **Adameyko, I., Lallemand, F., Furlan, A., Zinin, N., Aranda, S., Kitambi, S. S., Blanchart,**  
549 **A., Favaro, R., Nicolis, S., Lubke, M., et al. (2012).** Sox2 and Mitf cross-regulatory  
550 interactions consolidate progenitor and melanocyte lineages in the cranial neural  
551 crest. *Development* **139**, 397-410.

552 **Aktary, Z., Bertrand, J. U. and Larue, L. (2016).** The WNT-less wonder: WNT-independent  
553 beta-catenin signaling. *Pigment cell & melanoma research*.

554 **Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A.,**  
555 **Larue, L. and Goding, C. R. (2006).** Mitf regulation of Dia1 controls melanoma  
556 proliferation and invasiveness. *Genes Dev* **20**, 3426-3439.

557 **Colombo, S., Berlin, I., Delmas, V. and Larue, L. (2011).** Classical and non-classical  
558 melanocytes in vertebrates. In *Melanins and melanosomes* (ed. P. A. Riley & J.  
559 Borovansky), pp. 21-51. Weinheim: Wiley-VCH Verlag & Co.

560 **Curran, K., Raible, D. W. and Lister, J. A. (2009).** Foxd3 controls melanophore  
561 specification in the zebrafish neural crest by regulation of Mitf. *Dev Biol* **332**, 408-417.

562 **Delmas, V., Martinozzi, S., Bourgeois, Y., Holzenberger, M. and Larue, L. (2003).** Cre-  
563 mediated recombination in the skin melanocyte lineage. *Genesis* **36**, 73-80.

564 **Dorsky, R. I., Moon, R. T. and Raible, D. W. (1998).** Control of neural crest cell fate by the  
565 Wnt signalling pathway. *Nature* **396**, 370-373.

566 **Dupin, E., Glavieux, C., Vaigot, P. and Le Douarin, N. M. (2000).** Endothelin 3 induces the  
567 reversion of melanocytes to glia through a neural crest-derived glial-melanocytic  
568 progenitor. *Proc Natl Acad Sci U S A* **97**, 7882-7887.

569 **Dupin, E., Real, C., Glavieux-Pardanaud, C., Vaigot, P. and Le Douarin, N. M. (2003).**  
570 Reversal of developmental restrictions in neural crest lineages: transition from  
571 Schwann cells to glial-melanocytic precursors in vitro. *Proc Natl Acad Sci U S A* **100**,  
572 5229-5233.

573 **Furlan, A. and Adameyko, I. (2018).** Schwann cell precursor: a neural crest cell in disguise?  
574 *Dev Biol* **444 Suppl 1**, S25-S35.

- 575 **Gat, U., DasGupta, R., Degenstein, L. and Fuchs, E.** (1998). De Novo hair follicle  
576 morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin.  
577 *Cell* **95**, 605-614.
- 578 **Harada, N., Tamai, Y., Ishikawa, T., Sauer, B., Takaku, K., Oshima, M. and Taketo, M. M.**  
579 (1999). Intestinal polyposis in mice with a dominant stable mutation of the beta-  
580 catenin gene. *Embo J* **18**, 5931-5942.
- 581 **Hari, L., Brault, V., Kleber, M., Lee, H. Y., Ille, F., Leimeroth, R., Paratore, C., Suter, U.,**  
582 **Kemler, R. and Sommer, L.** (2002). Lineage-specific requirements of beta-catenin in  
583 neural crest development. *J Cell Biol* **159**, 867-880.
- 584 **Hirobe, T.** (1984). Histochemical survey of the distribution of the epidermal melanoblasts  
585 and melanocytes in the mouse during fetal and postnatal periods. *Anat Rec* **208**, 589-  
586 594.
- 587 **Hornyak, T. J., Hayes, D. J., Chiu, L. Y. and Ziff, E. B.** (2001). Transcription factors in  
588 melanocyte development: distinct roles for Pax-3 and Mitf. *Mech Dev* **101**, 47-59.
- 589 **Ikeya, M., Lee, S. M., Johnson, J. E., McMahon, A. P. and Takada, S.** (1997). Wnt  
590 signalling required for expansion of neural crest and CNS progenitors. *Nature* **389**,  
591 966-970.
- 592 **Imbert, A., Eelkema, R., Jordan, S., Feiner, H. and Cowin, P.** (2001). Delta N89 beta-  
593 catenin induces precocious development, differentiation, and neoplasia in mammary  
594 gland. *J Cell Biol* **153**, 555-568.
- 595 **Jacob, C.** (2015). Transcriptional control of neural crest specification into peripheral glia.  
596 *Glia*.
- 597 **Kinsler, V. A. and Larue, L.** (2018). The patterns of birthmarks suggest a novel population  
598 of melanocyte precursors arising around the time of gastrulation. *Pigment cell &*  
599 *melanoma research* **31**, 95-109.
- 600 **Kos, R., Reedy, M. V., Johnson, R. L. and Erickson, C. A.** (2001). The winged-helix  
601 transcription factor FoxD3 is important for establishing the neural crest lineage and  
602 repressing melanogenesis in avian embryos. *Development* **128**, 1467-1479.
- 603 **Kunisada, T., Yoshida, H., Yamazaki, H., Miyamoto, A., Hemmi, H., Nishimura, E.,**  
604 **Shultz, L. D., Nishikawa, S. and Hayashi, S.** (1998). Transgene expression of steel  
605 factor in the basal layer of epidermis promotes survival, proliferation, differentiation  
606 and migration of melanocyte precursors. *Development* **125**, 2915-2923.
- 607 **Laurette, P., Strub, T., Koludrovic, D., Keime, C., Le Gras, S., Seberg, H., Van Otterloo,**  
608 **E., Imrichova, H., Siddaway, R., Aerts, S., et al.** (2015). Transcription factor MITF  
609 and remodeler BRG1 define chromatin organisation at regulatory elements in  
610 melanoma cells. *Elife* **4**.
- 611 **Le Douarin, N. and Kalcheim, C.** (1999). *The neural crest* (Second edition edn).  
612 Cambridge: Cambridge University Press.
- 613 **Lee, H. Y., Kleber, M., Hari, L., Brault, V., Suter, U., Taketo, M. M., Kemler, R. and**  
614 **Sommer, L.** (2004). Instructive role of Wnt/beta-catenin in sensory fate specification  
615 in neural crest stem cells. *Science* **303**, 1020-1023.

- 616 **Luciani, F., Champeval, D., Herbette, A., Denat, L., Aylaj, B., Martinuzzi, S., Ballotti, R.,**  
617 **Kemler, R., Goding, C. R., De Vuyst, F., et al.** (2011). Biological and mathematical  
618 modeling of melanocyte development. *Development* **138**, 3943-3954.
- 619 **MacKenzie, M. A., Jordan, S. A., Budd, P. S. and Jackson, I. J.** (1997). Activation of the  
620 receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the  
621 mouse embryo. *Dev Biol* **192**, 99-107.
- 622 **Moon, K. R., Choi, Y. D., Kim, J. M., Jin, S., Shin, M. H., Shim, H. J., Lee, J. B. and Yun,**  
623 **S. J.** (2018). Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic  
624 Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological  
625 Features. *The Journal of investigative dermatology* **138**, 933-945.
- 626 **Nitzan, E., Krispin, S., Pfaltzgraff, E. R., Klar, A., Labosky, P. A. and Kalcheim, C.**  
627 (2013a). A dynamic code of dorsal neural tube genes regulates the segregation  
628 between neurogenic and melanogenic neural crest cells. *Development* **140**, 2269-  
629 2279.
- 630 **Nitzan, E., Pfaltzgraff, E. R., Labosky, P. A. and Kalcheim, C.** (2013b). Neural crest and  
631 Schwann cell progenitor-derived melanocytes are two spatially segregated  
632 populations similarly regulated by Foxd3. *Proceedings of the National Academy of*  
633 *Sciences of the United States of America* **110**, 12709-12714.
- 634 **Petit, V. and Larue, L.** (2016). Any route for melanoblasts to colonize the skin! *Exp*  
635 *Dermatol.*
- 636 **Real, C., Glavieux-Pardanaud, C., Le Douarin, N. M. and Dupin, E.** (2006). Clonally  
637 cultured differentiated pigment cells can dedifferentiate and generate multipotent  
638 progenitors with self-renewing potential. *Dev Biol* **300**, 656-669.
- 639 **Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D.,**  
640 **Kohlmeyer, J., Renn, M., Phung, B., Aymans, P., et al.** (2015). MITF and c-Jun  
641 antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine  
642 responsiveness and myeloid cell recruitment. *Nat Commun* **6**, 8755.
- 643 **Romagnolo, B., Berrebi, D., Saadi-Keddoucci, S., Porteu, A., Pichard, A. L.,**  
644 **Peuchmaur, M., Vandewalle, A., Kahn, A. and Perret, C.** (1999). Intestinal  
645 dysplasia and adenoma in transgenic mice after overexpression of an activated beta-  
646 catenin. *Cancer Res* **59**, 3875-3879.
- 647 **Silvers, W. K.** (1979). *The coat colors of Mice*. New York: Springer-Verlag.
- 648 **Steingrimsson, E., Copeland, N. G. and Jenkins, N. A.** (2004). Melanocytes and the  
649 microphthalmia transcription factor network. *Annu Rev Genet* **38**, 365-411.
- 650 **Steinhart, Z. and Angers, S.** (2018). Wnt signaling in development and tissue homeostasis.  
651 *Development* **145**.
- 652 **Thomas, A. J. and Erickson, C. A.** (2009). FOXD3 regulates the lineage switch between  
653 neural crest-derived glial cells and pigment cells by repressing MITF through a non-  
654 canonical mechanism. *Development* **136**, 1849-1858.
- 655 **Van Raamsdonk, C. D. and Deo, M.** (2013). Links between Schwann cells and melanocytes  
656 in development and disease. *Pigment cell & melanoma research* **26**, 634-645.

- 657 **Webster, D. E., Barajas, B., Bussat, R. T., Yan, K. J., Neela, P. H., Flockhart, R. J.,**  
658 **Kovalski, J., Zehnder, A. and Khavari, P. A.** (2014). Enhancer-targeted genome  
659 editing selectively blocks innate resistance to onco kinase inhibition. *Genome Res* **24**,  
660 751-760.
- 661 **Yajima, I., Belloir, E., Bourgeois, Y., Kumasaka, M., Delmas, V. and Larue, L.** (2006).  
662 Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. *Genesis* **44**,  
663 34-43.
- 664 **Yajima, I., Colombo, S., Puig, I., Champeval, D., Kumasaka, M., Belloir, E.,**  
665 **Bonaventure, J., Mark, M., Yamamoto, H., Taketo, M. M., et al.** (2013). A  
666 subpopulation of smooth muscle cells, derived from melanocyte-competent  
667 precursors, prevents patent ductus arteriosus. *PLoS ONE* **8**, e53183.
- 668 **Yamaguchi, Y., Itami, S., Watabe, H., Yasumoto, K., Abdel-Malek, Z. A., Kubo, T.,**  
669 **Rouzaud, F., Tanemura, A., Yoshikawa, K. and Hearing, V. J.** (2004).  
670 Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by  
671 palmoplantar fibroblasts inhibits melanocyte growth and differentiation. *J Cell Biol*  
672 **165**, 275-285.
- 673 **Yamaguchi, Y., Passeron, T., Hoashi, T., Watabe, H., Rouzaud, F., Yasumoto, K., Hara,**  
674 **T., Tohyama, C., Katayama, I., Miki, T., et al.** (2008). Dickkopf 1 (DKK1) regulates  
675 skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in  
676 keratinocytes. *FASEB J* **22**, 1009-1020.
- 677 **Zebary, A., Omholt, K., Vassilaki, I., Hoiom, V., Linden, D., Viberg, L., Kanter-**  
678 **Lewensohn, L., Johansson, C. H. and Hansson, J.** (2013). KIT, NRAS, BRAF and  
679 PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. *J*  
680 *Dermatol Sci* **72**, 284-289.  
681  
682

683 **FIGURE LEGENDS**

684

685 **Figure 1. Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup> mice present palmoplantar hyperpigmentation.**

686 A) Ventral views of WT and  $\beta$ catex3 anterior mouse paws in newborns (P1 and P5) and  
687 adults. B) Hematoxylin and eosin staining of P5 transversal paw sections. D = dorsal. V =  
688 ventral. Arrows point to pigmented cells. WT = (<sup>o</sup>/<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>) or (Tyr::Cre;  $\beta$ catex3<sup>+/+</sup>);  
689  $\beta$ cat $\Delta$ ex3 = (Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>).

690

691 **Figure 2. Overexpression of an active form of  $\beta$ -catenin induces hyperpigmented Dct-**  
692 **positive cells on the ventral side of the paws.**

693 WT-LacZ and  $\beta$ cat $\Delta$ ex3-LacZ P1 paws were transversally sectioned, and X-gal and eosin  
694 stained. (A) Anterior (ant.) and (B) posterior (post.) paws at the metacarpal and phalangeal  
695 levels, respectively. In the dermis, mutant paws display high numbers of Dct-positive cells  
696 (melanocytes stained in blue, directly under the dermo-epidermal junction of the  
697 palmoplantar side of the paws (A) and around the bones of the digits (B). Note that these  
698 cells show high accumulation of melanin. In the dermis, WT paws contain a very low number  
699 of Dct-positive cells or pigmentation. Note that some nerves are stained in blue in the  
700 posterior paws (red asterisk) in WT and mutant paws. WT-LacZ = (<sup>o</sup>/<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>;  
701 Dct::LacZ<sup>o</sup>);  $\beta$ cat $\Delta$ ex3-LacZ = (Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>; Dct::LacZ<sup>o</sup>).

702

703 **Figure 3.  $\beta$ -catenin favors the specification of SCPs towards melanoblasts.**

704 (A-C) The number of melanoblasts is higher on the ventral side of the distal limbs of  
705  $\beta$ cat $\Delta$ ex3 than WT mice. WT-LacZ and  $\beta$ cat $\Delta$ ex3-LacZ E14.5 (A) and E15.5 (B) paws were  
706 X-gal stained. Dorsal and ventral views are shown. The number of melanoblasts were  
707 estimated at E14.5 (C) in the distal (di) and proximal (pr) region of the limbs that are limited  
708 by dashed lines in (A). Arrows highlight ectopic melanoblasts. WT-LacZ = (<sup>o</sup>/<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>;  
709 Dct::LacZ<sup>o</sup>);  $\beta$ cat $\Delta$ ex3-LacZ = (Tyr::Cre<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>; Dct::LacZ<sup>o</sup>). (D-I) Melanoblast  
710 numbers in the paws are increased when  $\beta$ -catenin is activated at E10.5. Ventral views of  
711 WT-Tam and  $\beta$ cat $\Delta$ ex3-Tam E15.5 paws induced with 4OH-tamoxifen at E8.5 (D), E10.5 (E),  
712 and E11.5 (F) and X-gal stained. The number of melanoblasts was estimated at E15.5 in the  
713 distal (di) part of the paw that is delimited by the dashed lines in (D-F) after 4OH-tamoxifen  
714 induction at E8.5 (G), E10.5 (H), and E11.5 (I). Arrow in (E) highlights ectopic melanoblasts.  
715 No X-gal positive cells were observed at E15.5 when TAM induction was performed at E12.5.  
716 WT-Tam = (<sup>o</sup>/<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>; Dct::LacZ<sup>o</sup>);  $\beta$ cat $\Delta$ ex3-Tam = (Tyr::Cre-ER<sup>T2</sup>/<sup>o</sup>;  $\beta$ catex3<sup>fllox/+</sup>;  
717 Dct::LacZ<sup>o</sup>). Using an impaired t-test \*\*\* = p-value < 0.001, \*\* = p-value < 0.01 ns = non  
718 significant.

719

720 **Figure 4. The number of paw melanoblasts increases at the expense of glial cells**  
721 **when  $\beta$ -catenin is activated at E10.5**

722 Ventral views of WT-Tam and  $\beta$ cat $\Delta$ ex3-Tam E15.5 anterior paws from embryos induced  
723 with 4OH-tamoxifen at E10.5. Immunostainings for Mitf-M (green) and Gfap (red). A zoom at  
724 the level of the nerve is presented and highlights the reduction of Gfap positive cells in  
725  $\beta$ cat $\Delta$ ex3 paws compared to WT. WT-Tam = ( $^{\circ}/^{\circ}$ ;  $\beta$ catex3<sup>flox/+</sup>);  $\beta$ cat $\Delta$ ex3-Tam = (Tyr::Cre-  
726 ER<sup>T2</sup>/ $^{\circ}$ ;  $\beta$ catex3<sup>flox/+</sup>). The relative amounts of Gfap positive (Gfap +) and Mitf positive (Mitf +)  
727 cells are shown (WT vs.  $\beta$ cat $\Delta$ ex3). Statistical analysis was performed using an unpaired t-  
728 test. Error bars correspond to SEM. \*p < 0.05 and \*\*p<0.01.

729

730 **Figure 5. MITF represses *FOXD3* expression**

731 (A,B) The relative amounts of *FOXD3* and *AXIN2* were determined by RT-qPCR from the  
732 HEI-193 schwannoma cell line after siRNA mediated knockdown of APC. (C-F) The relative  
733 amounts of *FOXD3* (C,E) and *MITF* (D,F) were determined by RT-qPCR in 501mel and  
734 SK28 human melanoma cell lines after siRNA mediated knockdown of *MITF*, respectively.  
735 (G) UCSC screenshot of ChIP-seq data at the *FOXD3* locus. Shown are ChIP-seq data for  
736 H2AZ, BRG1 MITF and SOX10 in 501mel melanoma cells as previously described (GSE  
737 GSE61967) and for H3K27ac from GSM958157 (Laurette et al., 2015). MITF ChIP-seq in  
738 primary melanocytes (GSE50686) is from (Webster et al., 2014). Binding sites are indicated  
739 by arrows in the proximal promoter in primary melanocytes (Mc) and in a putative distal  
740 enhancer in Mc and 501mel cells. The DNA sequences under the peaks are shown along  
741 with the syntenic regions from mouse. MITF and SOX10 binding sites (BS) are highlighted in  
742 yellow. Each of these BS are bound by BRG1 and H2AZ; additional marks of regulatory  
743 sequences. Statistical analysis was performed using the unpaired t-test. Error bars  
744 correspond to SD. \*\*p < 0.01 and \*\*\*p<0.001.


745

746 **Figure 6. Schematic of the determination of SCP to generate Schwann cells and**  
747 **melanoblasts**

748


749






**Figure 1**

Colombo et al.



**Figure 2**

Colombo et al.



**Figure 3**




Figure 4





Figure 5




Figure 6

Colombo et al.